However, in the second week, the patient's fever rose up to 40°C, procalcitonin level increased to 15 ng/mL (
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Drug-induced pulmonary disease is an important consideration in the differential diagnosis of patients with rheumatoid arthritis (RA) who present with respiratory symptoms.
📊
Key Findings & Data:Pulse steroid was administered at 1000 mg/kg/day in the emergency department.
💡
Conclusion & Impact:However, in the second week, the patient's fever rose up to 40°C, procalcitonin level increased to 15 ng/mL (
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Drug-induced pulmonary disease is an important consideration in the differential diagnosis of patients with rheumatoid arthritis (RA) who present with respiratory symptoms. We report a patient with RA who developed acute respiratory failure two weeks after the administration of abatacept. The clinical findings were consistent with drug-induced acute respiratory failure, most likely acute eosinophilic pneumonia. Pulse steroid was administered at 1000 mg/kg/day in the emergency department. Chest X-ray and arterial blood gas values revealed significant improvement on the second day of hospitalization. However, in the second week, the patient's fever rose up to 40°C, procalcitonin level increased to 15 ng/mL (
🔖
Cite This Article
ÖKSÜZ, H., ÇETİN, G. Y., ATİLLA, N., DOĞU, B., YILMAZ, N. (2022). A case of acute respiratory failure in a rheumatoid arthritis patient after the administration of abatacept. European Journal of Rheumatology, Cilt: 3 - Sayı: 3, 46–47. https://ajindex.com/articles/511768
Makol A, Wright K, Matteson EL. Safe use of antirheu- matic agents in patients with comorbidities. Rheum Dis Clin North Am 2012; 38: 771-93. [CrossRef] Libby D, White DA. Pulmonary toxicity of drugs used to treat systemic autoimmune diseases. Clin Chest Med 1998; 19: 809-21. [CrossRef] Lateef O, Shakoor N, Balk RA. Methotrexate pul- monary toxicity. Expert Opin Drug Saf 2005; 4: 723-30. [CrossRef] Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostor AJ. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatolo- gy (Oxford) 2012; 51: 653-62. [CrossRef] Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434-8. [CrossRef] Quattrocchi E, Dallman MJ, Feldmann M. Ade- novirus-mediated gene transfer of CTLA-4 Ig fu- sion protein in the suppression of experimental autoimmune arthritis. Arthritis Rheum 2000; 43: 1688-97. [CrossRef] Orencia (abatacept) full prescribing informa- tion. Available from: http://packageinserts.bms. com/pi/pi_orencia.pdf Wada T, Akiyama Y, Yokota K, Sato K, Funakubo Y, Mimura T. A case of rheumatoid arthritis compli- cated with deteriorated interstitial pneumonia af- ter the administration of abatacept. Nihon Rinsho Meneki Gakkai Kaishi 2012; 35: 433-8. [CrossRef] Kato K, Satoh T, Nishizawa A, Yokozeki H. Psori- asiform drug eruption due to abatacept. Acta Derm Venereol 2011; 91: 362-3. [CrossRef] Pieper J, Herrath J, Raghavan S, Muhammad K, Vol- lenhoven Rv, Malmström V. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in au- toantibody-positive rheumatoid arthritis patients. BMC Immunol 2013; 14: 34. [CrossRef] 135